RT Journal Article
SR Electronic
T1 α-Labeling of J591, an Antibody Targeting Prostate-Specific Membrane Antigen: The Technique and Considerations from the First Dedicated Production Lab at an Academic Institution in the United States
JF Journal of Nuclear Medicine Technology
JO J. Nucl. Med. Technol.
FD Society of Nuclear Medicine
SP 215
OP 219
DO 10.2967/jnmt.122.265166
VO 51
IS 3
A1 Subramanian, Kritika
A1 Stangl-Kremser, Judith
A1 Sawoszczyk, Lady
A1 Avlonitis, Vasilios
A1 Gernerd, Andrew
A1 Nixon, Kyla
A1 Zgaljardic, Michael
A1 Tagawa, Scott
A1 Bander, Neil
A1 Osborne, Joseph R.
YR 2023
UL http://tech.snmjournals.org/content/51/3/215.abstract
AB The protein expression of the prostate-specific membrane antigen correlates with unfavorable or aggressive histologic features of prostate cancer, resulting in use as a diagnostic PET imaging radiotracer and therapeutic target. Here, we discuss the methods to develop 225Ac-DOTA-J591, an α-labeled compound targeting an extracellular epitope of prostate-specific membrane antigen, which is currently being studied in early clinical trials. In addition, we review quality control, radiation safety measures, and clinical considerations before administration of this radioimmunotherapeutic agent.